MedTrace Logo

Tranexamic Acid as an Intervention in Placenta Previa

NCT05688111 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2025-01-27

No results posted yet for this study

Summary

Antepartum hemorrhage (APH) due to placenta previa is an important cause of worldwide perinatal mortality and maternal morbidity in pregnant women

Conditions

  • Interventional Drug in Placenta Previa

Interventions

DRUG

Tranexamic acid injection

Active group will receive 1gm Tranexamic acid 12 hourly for 48 hours

OTHER

Glucose water 5%

Placebo group 30ml will be received 12 hourly for 48 hours

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • SHAHLA K ALALAF, prof. · Hawler Medical University

  • Ariana Jawad, professor · Kurdistan Higher Counsel of Medical Specialties

  • khalida Amin, Ass. Prof · karkuk Medical college

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-10
Primary Completion
2023-12-03
Completion
2023-12-03

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05688111 on ClinicalTrials.gov